|
Market Closed -
Other stock markets
|
After hours 02:09:33 am | |||
| 59.08 USD | +0.22% |
|
58.89 | -0.32% |
| 04:34pm | Health Rounds: Eliquis proves safer than Xarelto for patients with deep blood clots | RE |
| 10/03 | BioNTech founders plan exit to set up new venture, shares slump | RE |
| Capitalization | 12TCr 10TCr 9.48TCr 9.07TCr 16TCr 11,10400Cr 17TCr 1,13300Cr 45TCr 5,30500Cr 45TCr 44TCr 19,16000Cr | P/E ratio 2026 * |
11.8x | P/E ratio 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise value | 15TCr 13TCr 12TCr 11TCr 20TCr 13,55000Cr 21TCr 1,38200Cr 55TCr 6,47400Cr 55TCr 54TCr 23,38200Cr | EV / Sales 2026 * |
3.11x | EV / Sales 2027 * | 3.07x |
| Free-Float |
67.93% | Yield 2026 * |
4.27% | Yield 2027 * | 4.39% |
Last Transcript: Bristol-Myers Squibb Company
| 1 day | -0.10% | ||
| 1 week | -2.01% | ||
| Current month | -5.27% | ||
| 1 month | -2.73% | ||
| 3 months | +8.82% | ||
| 6 months | +27.46% | ||
| Current year | +9.53% |
| 1 week | 58.32 |  | 60.96 |
| 1 month | 58.32 | | 62.89 |
| Current year | 52.06 | | 62.89 |
| 1 year | 42.52 | | 62.89 |
| 3 years | 39.35 | | 71.06 |
| 5 years | 39.35 | | 81.44 |
| 10 years | 39.35 | | 81.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 01/11/2023 | |
David Elkins
DFI | Director of Finance/CFO | 58 | 20/11/2019 |
| Compliance Officer | - | 01/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 55 | 01/04/2024 | |
Peter Arduini
BRD | Director/Board Member | 61 | 01/04/2016 |
Theodore Samuels
BRD | Director/Board Member | 71 | 21/02/2017 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +0.07% | 12.97% | 253 M€ | |
| -3.15% | 4.01% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.22% | -2.01% | -1.99% | -10.48% | 12TCr | |
| +0.80% | -0.53% | +22.88% | +203.58% | 87TCr | |
| -0.21% | +0.47% | +48.18% | +57.79% | 58TCr | |
| -2.52% | -4.53% | +3.84% | +44.57% | 40TCr | |
| +0.79% | -8.76% | +4.36% | +21.64% | 32TCr | |
| +0.11% | -2.67% | +23.43% | +34.42% | 30TCr | |
| +0.43% | -2.77% | +26.01% | +62.64% | 29TCr | |
| -0.26% | -0.16% | +22.07% | +9.34% | 29TCr | |
| -0.43% | -0.90% | +17.13% | +57.05% | 20TCr | |
| +0.42% | +0.74% | +27.91% | +82.35% | 18TCr | |
| Average | +0.09% | -2.10% | +19.38% | +56.29% | 35.55TCr | |
| Weighted average by Cap. | +0.24% | -1.79% | +22.54% | +82.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.71TCr 4.12TCr 3.72TCr 3.56TCr 6.47TCr 4,35900Cr 6.73TCr 44TCr 18TCr 2,08200Cr 18TCr 17TCr 7,52100Cr | 4.58TCr 4TCr 3.62TCr 3.46TCr 6.29TCr 4,23400Cr 6.54TCr 43TCr 17TCr 2,02300Cr 17TCr 17TCr 7,30700Cr |
| Net income | 1.03TCr 896.42Cr 809.86Cr 774.73Cr 1.41TCr 95TCr 1.46TCr 9.67TCr 3.83TCr 45TCr 3.85TCr 3.77TCr 1,63700Cr | 1.01TCr 885.29Cr 799.81Cr 765.11Cr 1.39TCr 94TCr 1.45TCr 9.55TCr 3.79TCr 45TCr 3.8TCr 3.72TCr 1,61600Cr |
| Net Debt | 2.64TCr 2.31TCr 2.09TCr 2TCr 3.63TCr 2,44600Cr 3.78TCr 25TCr 9.89TCr 1,16900Cr 9.93TCr 9.72TCr 4,22100Cr | 2.05TCr 1.79TCr 1.62TCr 1.55TCr 2.82TCr 1,89800Cr 2.93TCr 19TCr 7.67TCr 91TCr 7.7TCr 7.54TCr 3,27500Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/26/14 | 59.08 $ | +0.22% | 93,66,777 |
| 12/26/12 | 58.95 $ | -1.72% | 1,02,35,100 |
| 11/26/11 | 59.98 $ | -0.25% | 90,43,759 |
| 10/26/10 | 60.13 $ | -0.82% | 96,93,803 |
| 09/26/09 | 60.63 $ | +0.56% | 1,09,64,649 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BMY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition